Crizotinib in ALK-positive lung cancer

被引：4
|
作者：
Girard, Nicolas [1 ]
机构：
[1] Louis Pradel Hosp, F-69500 Bron, France
来源：
LANCET ONCOLOGY | 2012年 / 13卷 / 10期
关键词：
ANAPLASTIC LYMPHOMA; CELL; KINASE;
D O I：
10.1016/S1470-2045(12)70375-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：962 / 963
页数：2
相关论文
共 50 条
  • [1] Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Nakagawa, Kazuhiko
    Seto, Takashi
    Crino, Lucio
    Ahn, Myung-Ju
    De Pas, Tommaso
    Besse, Benjamin
    Solomon, Benjamin J.
    Blackhall, Fiona
    Wu, Yi-Long
    Thomas, Michael
    O'Byrne, Kenneth J.
    Moro-Sibilot, Denis
    Camidge, D. Ross
    Mok, Tony
    Hirsh, Vera
    Riely, Gregory J.
    Iyer, Shrividya
    Tassell, Vanessa
    Polli, Anna
    Wilner, Keith D.
    Jaenne, Pasi A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (25): : 2385 - 2394
  • [2] Crizotinib versus chemotherapy in advanced ALK-positive lung cancer
    Thibault, Constance
    Teixeira, Luis
    ONCOLOGIE, 2013, 15 (09) : 494 - 495
  • [3] First-Line Crizotinib in ALK-Positive Lung Cancer
    Tural, Deniz
    Kilickap, Saadettin
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 781 - 781
  • [4] The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer
    Pender, Alexandra
    Popat, Sanjay
    THERAPEUTIC ADVANCES IN RESPIRATORY DISEASE, 2015, 9 (03) : 97 - 104
  • [5] Expanding opportunities for crizotinib resistance in ALK-positive lung cancer patients
    Ilie, Marius
    Hofman, Paul
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 (02) : 203 - 205
  • [6] Induction of autophagy contributes to crizotinib resistance in ALK-positive lung cancer
    Ji, Cheng
    Zhang, Li
    Cheng, Yan
    Patel, Raj
    Wu, Hao
    Zhang, Yi
    Wang, Mian
    Ji, Shundong
    Belani, Chandra P.
    Yang, Jin-Ming
    Ren, Xingcong
    CANCER BIOLOGY & THERAPY, 2014, 15 (05) : 570 - 577
  • [7] First-Line Crizotinib in ALK-Positive Lung Cancer REPLY
    Solomon, Benjamin J.
    Mok, Tony
    NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (08): : 782 - 782
  • [8] First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
    Solomon, Benjamin J.
    Mok, Tony
    Kim, Dong-Wan
    Wu, Yi-Long
    Nakagawa, Kazuhiko
    Mekhail, Tarek
    Felip, Enriqueta
    Cappuzzo, Federico
    Paolini, Jolanda
    Usari, Tiziana
    Iyer, Shrividya
    Reisman, Arlene
    Wilner, Keith D.
    Tursi, Jennifer
    Blackhall, Fiona
    Boyer, M.
    Ganju, V.
    Hughes, B.
    Pavlakis, N.
    Solomon, B.
    Varma, S.
    Berghmans, T.
    Canon, J-L
    Demedts, I.
    Janssens, A.
    Louis, R.
    Pieters, T.
    Schallier, D.
    Surmont, V.
    da Silva, C. Maciel
    Ferreira, C-G Moreira
    Hirsh, V.
    Joy, A.
    Laberge, F.
    Morzycki, W.
    Wierzbicki, R.
    Han, B.
    Liu, X.
    Qin, S.
    Shi, Y.
    Wang, Y.
    Wu, G.
    Wu, Y-L
    Zhou, C.
    Ahvonen, J.
    Barlesi, F.
    Cadranel, J.
    Dansin, E.
    Fayette, J.
    Morere, J-F
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (23): : 2167 - 2177
  • [9] First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
    Shaw, Alice T.
    Bauer, Todd M.
    de Marinis, Filippo
    Felip, Enriqueta
    Goto, Yasushi
    Liu, Geoffrey
    Mazieres, Julien
    Kim, Dong-Wan
    Mok, Tony
    Polli, Anna
    Thurm, Holger
    Calella, Anna M.
    Peltz, Gerson
    Solomon, Benjamin J.
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (21): : 2018 - 2029
  • [10] J-ALEX: alectinib versus crizotinib in ALK-positive lung cancer
    Gainor, Justin F.
    Shaw, Alice T.
    LANCET, 2017, 390 (10089): : 3 - 4
12345